Neurofibrillary tangles in Alzheimer′s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
As a key contributor to memory storage, the synapse is one of the earliest affected neuronal components in Alzheimers disease (AD). Under physiological conditions, the synaptic connections between neurons undergo activity-dependent functional and morphological re-organisation. This dynamic, ‘plastic’ neural ability critically depends on the structural integrity of the synapse. Thus, proteins that are implicated in preserving the organisation and dynamics of synaptic connections, including microtubules of the cytoskeleton and associated proteins, have attracted much focus for their involvement in the malfunctioning AD synapse. Neurofibrillary tangles (NFTs) are a fundamental neuropathological hallmark of AD. NFT-bearing neurons have been characterised by loss of cytoskeletal microtubules and tubulin-associated proteins. Although the exact molecular mechanisms linking the loss of cytoskeletal elements to NFT development remain unclear, signal transduction pathways involving protein phosphorylation and de-phosphorylation are likely to play a central role in the formation of neurofibrillary lesions (Figure 1). For instance, the major constituent of NFTs, the microtubule-associated protein tau (Mapt), is abnormally phosphorylated (hyperphosphorylated) in the brains of AD patients compared to non-demented individuals (Zempel and Mandelkow, 2014). Hyperphosphorylation occurs in an epitope-specific manner during the course of AD, and is known to underlie the missorting of tau from a primarily axonal to a somatodendritic location in neurons. This alteration is thought to contribute not only to the deregulation of microtubule dynamics, but also to tau polymerisation and aggregation (Alonso et al., 2008).Figure 1: Neuronal phospho-signallingand tangle formation.The figure shows a post-synaptic neuron with its nucleus. After stimulation of ion-channels and/or G protein-coupled receptors via neurotransmitters originating from the presynapse, phospho-signalling associated with long-term potentiation (activation of phosphorylation) or long-term depression (suppression of phosphorylation), including Ca2+-, MAPK, PI3K or cAMP-mediated signalling is activated/inhibited. This can lead to changes in the phosphorylation status of down-stream targets such as stathmin1 or 14-3-3 proteins, which may in turn induce an altered phosphorylation profile of tau protein that can eventually culminate in NFT formation. Neuronal cellular metabolism is also important in this process, where cell cycle signalling may lead to an increased phosphorylation of Cdk proteins affecting NFT formation. Phosphorylation defects in stathmin1, 14-3-3 and Cdk (such as Cdk5) proteins have been shown to be involved in Alzheimer's neuropathology. cAMP: Cyclic adenosine monophosphate; Cdk: cyclin-dependent kinase; MAPK: mitogen-activated protein kinases; NFT: neurofibrillary tangles; PI3K: phosphoinositide 3-kinase. The figure was generated by images from commercial software (http://www.visiscience.com).Conceivably, investigating the molecular mechanisms behind the causes and consequences of Mapt hyperphosphorylation may lead to an improved understanding of the protein's role in NFT formation, and further elucidate the connection between NFT deposition, synaptic loss and memory impairment in AD. Interestingly, formation of NFTs and synapse loss are correlated during the course of AD (Gomez-Isla et al., 1997) and each of these processes further correlates with cognitive decline, arguing that these AD lesions occur in a related, rather than independent manner. Immunohistochemistry of phospho-sites related to Mapt in human post-mortem brain and in mice with amyloid pathology: The regional progression of neurofibrillary lesions is highly stereotyped in the AD brain. In their landmark study of 1991, Braak and Braak used post-mortem tissue from demented and non-demented individuals to summarise three stages of propagation of tau-related pathology (Braak and Braak, 1991). In the Braak staging system, NFTs appear initially in the trans-entorhinal region of the temporal lobe, spreading to limbic areas such as the hippocampus, and finally affecting large areas of the neocortex. In addition to the region-specific spread of NFTs, distinct morphological stages of NFT formation have been also discerned in the AD brain. Each individual stage has been associated with characteristic patterns of Mapt hyperphosphorylation, suggesting that specific phosphorylation events may contribute to the evolution of tau pathology (Augustinack et al., 2002). Thus, pre-NFTs are typically observed as punctuate or diffuse tau inclusions within the cytoplasm of an otherwise normal-looking neuron, and are preferentially labelled by antibodies to tau phospho-epitopes pSer262, pThr153 and pThr231. Mature NFTs, most intensely stained with antibodies to tau epitopes of pThr175/181, pSer46, pSer214, pSer262/pSer356 and pSer422 are compact filamentous aggregates of cytoplasmic tau that invariably displa
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“In their landmark study of 1991, Braak and Braak used post-mortem tissue from demented and non-demented individuals to summarise three stages of propagation of tau-related pathology (Braak and Braak, 1991).”
BackgroundNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“Interestingly, formation of NFTs and synapse loss are correlated during the course of AD (Gomez-Isla et al., 1997) and each of these processes further correlates with cognitive decline, arguing that these AD lesions occur in a related, rather than independent manner.”
BackgroundAugustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 2×
“Each individual stage has been associated with characteristic patterns of Mapt hyperphosphorylation, suggesting that specific phosphorylation events may contribute to the evolution of tau pathology (Augustinack et al., 2002).”
BackgroundIdentification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527 · cited 1×
“Indeed, it has been proposed that phosphorylation at Thr231 is an initiating event for the formation of NFTs, followed by oligomeric tau aggregation, filament formation, and neuronal cell death (Lasagna-Reeves et al., 2012).”
BackgroundMorris, M., Knudsen, G. M., Maeda, S., Trinidad, J. C., Ioanoviciu, A., Burlingame, A. L., & Mucke, L. (2015) · Nature Neuroscience · doi:10.1038/nn.4067 · Cited by 472 · cited 5×
“confirmed 41 and identified 22 novel tau modifications, including phosphorylations, methylations, acetylations and ubiquitinations (Morris et al., 2015).”
BackgroundMethodInfluentialLost after translation: missorting of Tau protein and consequences for Alzheimer disease
Zempel, H., & Mandelkow, E. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.08.004 · Cited by 265 · cited 1×
“For instance, the major constituent of NFTs, the microtubule-associated protein tau (Mapt), is abnormally phosphorylated (hyperphosphorylated) in the brains of AD patients compared to non-demented individuals (Zempel and Mandelkow, 2014).”
BackgroundModels of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256 · cited 1×
“…of NFT formation, amount and propagation, a growing body of preclinical studies has shown amyloid beta-induced phosphorylation of endogenous mouse tau in vivo, using antibodies to the aforementioned tau epitopes and techniques such as immunohistochemistry and western blotting (Stancu et al., 2014).”
BackgroundFunk, K. E., Thomas, S. N., Schafer, K. N., Cooper, G. L., Liao, Z., Clark, D. J., Yang, A. J., & Kuret, J. (2014) · Biochemical Journal · doi:10.1042/bj20140372 · Cited by 142 · cited 1×
“The majority of altered phosphorylation sites of Mapt were adjacent to the microtubule-binding repeat domain, and were comparable in number with phosphosites identified from wild-type mice or post-mortem brain tissue from non-demented humans (Funk et al., 2014).”
BackgroundMechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Alonso, A. D., Li, B., Grundke-Iqbal, I., & Iqbal, K. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132307 · Cited by 129 · cited 1×
“This alteration is thought to contribute not only to the deregulation of microtubule dynamics, but also to tau polymerisation and aggregation (Alonso et al., 2008).”
BackgroundDi Domenico, F., Sultana, R., Barone, E., Perluigi, M., Cini, C., Mancuso, C., Cai, J., Pierce, W. M., & Butterfield, D. A. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.03.033 · Cited by 91 · cited 1×
“Moreover, our efforts to characterise phosphosites on Mapt and other proteins should be quantitative rather than limited to basic event identification, as shown by Di Domenico et al. (2011) in the hippocampus of AD patients using 2D gels.”
BackgroundExplorative and targeted neuroproteomics in Alzheimer's disease
Brinkmalm, A., Portelius, E., Öhrfelt, A., Brinkmalm, G., Andréasson, U., Gobom, J., Blennow, K., & Zetterberg, H. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.009 · Cited by 47 · cited 1×
“A key challenge relates to the long post-mortem interval times for obtaining human tissue, a delay which may itself induce secondary and tertiary processes in the (phospho-)proteomic profiles, obscuring changes due to the primary causes of AD (Brinkmalm et al., 2015).”
BackgroundKempf, S. J., Metaxas, A., Ibáñez-Vea, M., Darvesh, S., Finsen, B. R., & Larsen, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.9092 · Cited by 46 · cited 4×
“Our phosphoproteomics approach further revealed that Ser16 phosphorylation of the microtubule-binding protein stathmin1 was decreased in the cortex, but increased in the olfactory bulb of APPswe/PS1ΔE9 compared to wild-type mice (Kempf et al., 2016).”
BackgroundMethodSelf-citation
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60
Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease
Chowdhury, M. R., Jin, H. K., & Bae, J.-S. (2022) · Biomedicines · doi:10.3390/biomedicines10081956 · Cited by 47
Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease
Arora, T., Prashar, V., Singh, R., Barwal, T. S., Changotra, H., Sharma, A., & Parkash, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02950-z · Cited by 37
Metadata
- Authors
- Kempf, S., & Metaxas, A.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2016
- Volume
- 11
- Issue
- 10
- Pages
- 1579
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W2528806486
- Cited by
- 160
- References
- 12
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.